Eveline Verheij

Eveline Verheij

Auto-generated profile, based on publicly available information

Eveline Verheij

Division of Infectious Diseases, Amsterdam Infection and Immunity Institute, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands; Department of Global Health, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2023 in The Lancet HIV
Verified
Journal Article
Closed access
EVEveline Verheij
Eveline Verheij
ABAnders Boyd
Anders Boyd
FWFerdinand W Wit
Ferdinand W Wit
SVSebastiaan O Verboeket
Sebastiaan O Verboeket
MVMyrthe L Verburgh
Myrthe L Verburgh
LVL. Vogt
L. Vogt

20 January 2020 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
EVEveline Verheij
Eveline Verheij
GKGregory D Kirk
Gregory D Kirk
FWFerdinand W Wit
Ferdinand W Wit
RZRosan A van Zoest
Rosan A van Zoest
SVSebastiaan O Verboeket
Sebastiaan O Verboeket
FCfor the AGEhIV Cohort
for the AGEhIV Cohort
Background: Frailty is associated with mortality and morbidity in the general geriatric population, but less is known about its impact among the aging but generally younger population with human immunodeficiency virus (HIV). Methods: The impact of frailty on all-cause mortality during 6 years of follow-up and incident comorbidity during 4 years of follow-up was assessed among 598 HIV-positive and 550 comparable HIV-negative participants aged ≥ 45 years of the AGEhIV Cohort Study. Frailty encompasses 5 domains; weight loss, low physical activity, exhaustion, decreased grip strength, and slow gait speed. Presence of ≥ 3 denotes frailty, 1–2 prefrailty, and 0 robust. Multivariable Cox and logistic regression models were used to assess the independent relationships of frailty with both outcomes, adjusting for HIV infection and traditional risk factors. Results: At baseline, 7.5% (n = 86) of participants were frail. During follow-up, 38 participants died. Mortality rate was significantly higher among frail participants: 25.7/1000 person-years of follow-up (PYFU) (95% confidence interval [CI], 14.2–46.4) compared with prefrail (7.2/1000 PYFU [95% CI, 4.7–11.2]) and robust (2.3/1000 PYFU [95% CI, 1.1–4.9]). In fully adjusted analyses, frailty remained strongly associated with death (hazard ratio, 4.6 [95% CI, 1.7–12.5]) and incident comorbidity (odds ratio, 1.9 [95% CI, 1.1–3.1]). No interactions were observed between frailty and HIV status in all analyses. Conclusions: Frailty is a strong predictor of both mortality and incident comorbidity independent from other risk factors. Clinical Trials Registration: NCT01466582.

16 October 2020 in JAIDS Journal of Acquired Immune Deficiency Syndromes
Verified
Journal Article
Open access
EVEveline Verheij
Eveline Verheij
FWFerdinand Wit
Ferdinand Wit
SVSebastiaan O. Verboeket
Sebastiaan O. Verboeket
MLMaarten F. Schim van der Loeff
Maarten F. Schim van der Loeff
JNJeannine F. Nellen
Jeannine F. Nellen
GKGregory D. Kirk
Gregory D. Kirk
Background: We previously demonstrated a higher prevalence of frailty among AGEhIV-cohort participants with HIV (PWH) than among age- and lifestyle-comparable HIV-negative participants. Furthermore, frailty was associated with the development of comorbidities and mortality. As frailty may be a dynamic state, we evaluated the frequency of transitions between frailty states, and explored which factors were associated with transition toward frailty in this cohort. Methods: The study enrolled 598 PWH and 550 HIV-negative participants aged ≥45 years. Of those, 497 and 479 participants, respectively, participated in ≥2 consecutive biennial study-visits between October 2010 and October 2016, contributing 918 and 915 visit-pairs, respectively. We describe the frequency, direction, and risk factors of frailty transitions. Logistic regression models with generalized estimating equations were used to evaluate determinants for transition to frailty, including HIV-status, socio-demographic, behavioral, HIV-related factors, and various inflammatory and related biomarkers. Results: Transitioning between frailty states in any direction occurred in 36% of a total of 1833 visit-pairs. The odds of nonfrail participants transitioning toward frailty were significantly higher for PWH, occurring in 35 PWH (7.3%) and 25 (5.2%) HIV-negative nonfrail participants, respectively (odd ratioHIV 2.19, 95% confidence interval 1.28 to 3.75). The increased risk among PWH was attenuated when sequentially adjusting for waist–hip ratio, number of pre-existent comorbidities, and the presence of depressive symptoms. Conclusion: PWH are at increased risk of transitioning to frailty, and thereby at increased risk of adverse health outcomes. Whether optimizing the management of obesity, comorbidity, or depressive symptoms may modify the risk of becoming frail requires further investigation.